| Literature DB >> 31506564 |
Roberta Bottega1, Maria D Perrone1, Katy Vecchiato2, Andrea Taddio1,2, Subrata Sabui3, Vanna Pecile1, Hamid M Said3,4, Flavio Faletra5.
Abstract
Thiamine metabolism dysfunction syndrome-4 (THMD4) includes episodic encephalopathy, often associated with a febrile illness, causing transient neurologic dysfunction and a slowly progressive axonal polyneuropathy. Until now only two mutations (G125S and S194P) have been reported in the SLC25A19 gene as causative for this disease and a third mutation (G177A) as related to the Amish lethal microcephaly. In this work, we describe the clinical and molecular features of a patient carrying a novel mutation (c.576G>C; Q192H) on SLC25A19 gene. Functional studies on this mutation were performed explaining the pathogenetic role of c.576G>C in affecting the translational efficiency and/or stability of hMTPPT protein instead of the mRNA expression. These findings support the pathogenetic role of Q192H (c.576G>C) mutation on SLC25A19 gene. Moreover, despite in other patients the thiamine supplementation leaded to a substantial improvement of peripheral neuropathy, our patient did not show a clinical improvement.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31506564 PMCID: PMC6886476 DOI: 10.1038/s10038-019-0666-5
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172